XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: May 2, 2024
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
More >>
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>